Regeneron price target raised to $205 from $176 at RW Baird Baird raised its price target on Regeneron following the its recent bullish Eylea survey which indicated the drug's uptake trajectory remains strong. The firm believes the EU roll-out of Eylea and late stage pipeline will push the share price to its price target. Shares are Outperform rated.
News For REGN From The Last 14 Days
Check below for free stories on REGN the last two weeks.